OS Therapies Inc

OS Therapies Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing immunotherapy and targeted cancer candidates. Its lead programs include OST-HER2 for osteosarcoma and OST-tADC, with development activities centered on preclinical work, clinical trials, and regulatory submissions.

0.03

0.03

— OS Therapies Inc
%
OST-HER270% Lead therapeutic candidate for osteosarcoma and other HER2-related oncology uses.
OST-tADC20% Next-generation targeted antibody-drug conjugate platform under development.
Preclinical and discovery programs5% Early-stage research, assay work, and candidate modeling activities.
OS Animal Health5% Subsidiary-related strategic alternatives and animal health activities.

OS Therapies does not sell commercial products in the traditional sense; its primary counterparties are regulators,...

  • Regulators and health authoritiesprimary

    FDA, MHRA, and EMA review clinical data and marketing applications for OST-HER2.

  • Clinical development vendorsprimary

    CROs, CDMOs, consultants, and labs provide trial execution, manufacturing, and testing.

  • Oncology patientsprimary

    Patients with recurrent osteosarcoma and other HER2-related solid tumors are the eventual end users.

  • Healthcare providerssecondary

    Hospitals and oncologists would prescribe or administer the therapy if approved.

  • Research collaboratorssecondary

    Academic and clinical partners may support biomarker analysis and future expansion studies.

OS Therapies is headquartered in the United States and conducts its development, regulatory, and corporate activities...

  • •United States is the corporate base and primary operating center
  • •U.S. FDA pathway is central to OST-HER2 development
  • •United Kingdom MHRA is a planned filing jurisdiction
  • •European Medicines Agency is another key approval pathway
  • •International development matters because approvals may be multi-region

The company’s near-term strategy is to advance OST-HER2 through late-stage regulatory and pre-commercial milestones,...

01
Regulatory submission for OST-HER2short-term

Approval is the main value-creation event for a clinical-stage oncology company.

02
Biomarker and clinical evidence generationshort-term

Clinical endpoint support is needed to strengthen the approval case.

03
Pipeline expansion beyond osteosarcomamedium-term

Broader indications could increase the commercial value of the platform.

04
Next-generation platform developmentmedium-term

OST-tADC modeling may create a second development engine beyond OST-HER2.

OS Therapies faces the classic risks of a development-stage biotech company: clinical failure, regulatory rejection,...

critical

Regulatory approval risk

OST-HER2 must satisfy agency standards for safety and efficacy before commercialization.

Scope
FDA, MHRA, EMA
Materiality
high
critical

Clinical development risk

Phase IIb and biomarker data may not translate into approvable outcomes.

Scope
OST-HER2 and future pipeline programs
Materiality
high
high

Financing and dilution risk

The company has no product revenue and depends on external capital to fund operations.

Scope
Convertible notes, warrants, equity offerings
Materiality
high
medium

Vendor and outsourcing execution risk

Development work relies on CROs, CDMOs, labs, and consultants for trial and manufacturing tasks.

Scope
Preclinical and clinical operations
Materiality
medium
medium

Dilution and trading pressure from securities overhang

Outstanding warrants, options, and preferred stock can increase share supply and affect valuation.

Scope
Common stock
Materiality
medium
Research and development expense recognition
Affects operating loss and comparability across quarters
Warrant liability valuation
Can create non-cash gains or losses
Stock-based compensation
Raises reported operating expenses without cash outflow
Equity financing and dilution accounting
Changes share count and balance sheet presentation

Vivos Therapeutics, Inc.

VVOS · Surgical & Medical Instruments & Apparatus

TransMedics Group, Inc.

TMDX · Electromedical & Electrotherapeutic Apparatus

VIVOS INC

RDGL · Surgical & Medical Instruments & Apparatus

Ovid Therapeutics Inc.

OVID · Pharmaceutical Preparations

Opus Genetics, Inc.

IRD · Pharmaceutical Preparations

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

: 29.4.2026